John Wayne Cancer Institute
General Surgery
Dr. Mark B. Faries, MD
|
|
Give Review
Mark Faries works in the field of General Surgery. She attended Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine She received awards:"Top Doctors:LA Area" and "Fellow (FACS)". Mark Faries is also a published doctor. She has 70 paper published. The most recent paper is: Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. Mark Faries accepts all Medicare patients.
Publications
- Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial.
- Predictors and Survival Impact of False-Negative Sentinel Nodes in Melanoma.
- Attitudes and Perceptions of Surgical Oncology Fellows on ACGME Accreditation and the Complex General Surgical Oncology Certification.
- Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.
- Metastasectomy for Stage IV Melanoma.
- Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: Response to 'No survival benefit f...
- Melanoma Vaccines: Mixed Past, Promising Future.
- Final trial report of sentinel-node biopsy versus nodal observation in melanoma.
- Late recurrence in melanoma: clinical implications of lost dormancy.
- Staging of Regional Lymph Nodes in Melanoma: A Case for Including Nonsentinel Lymph Node Positivity in the American Joint Committee on Cancer Staging System.
- Comparative Evaluation of [(99m)Tc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials.
- Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneo...
- Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicen...
- Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques.
- Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma.
- Staging of Regional Nodes in Pulmonary Malignancies.
- Diverting ileostomies: primum minus nocere (first, do less harm).
- Local and intralesional therapy of in-transit melanoma metastases.
- Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion.
- Reply to Letter to the Editor "Lymphoedema in the Observation and Biopsy Arms of MSLT-1" by Thomas, J Meirion (ASO-2011-04-0666).
- Current surgical treatment in melanoma.
- Management of popliteal sentinel nodes in melanoma.
- Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.
- Predictors of occult nodal metastasis in colon cancer: results from a prospective multicenter trial.
- Predictors of occult nodal metastasis in patients with thin melanoma.
- Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?
- Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.
- Does specialized surgical training increase lymph node yield in colon cancer?
- Improved survival for stage IV melanoma from an unknown primary site.
- Age-related lymphatic dysfunction in melanoma patients.
- Solitary dermal melanoma: beginning or end of the metastatic process?
- Importance of sentinel lymph node biopsy in patients with thin melanoma.
- Management decisions for nodal metastasis from an unknown primary melanoma.
- Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
- Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.
- Surgery and sentinel lymph node biopsy.
- A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
- The promise of metastasectomy in melanoma.
- Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes?
- Evaluation of immunotherapy in the treatment of melanoma.
- Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma.
- Dendritic cells in melanoma immunotherapy.
- Lymphatic mapping and sentinel lymphadenectomy for primary and metastatic pulmonary malignant neoplasms.
- Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer ...
- The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making.
- Melanoma: is immunotherapy of benefit?
- Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.
- Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines.
- Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology.
- Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase.
- Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function.
- Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase.
- Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status.
- Use of gastrostomy and combined gastrojejunostomy tubes for enteral feeding.
- Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development.
- Radiofrequency ablation of hepatic malignancies: inexpensive and minimally invasive but should it replace resection?
- Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.
- Therapeutic vaccines for melanoma: current status.
- Vaccine therapy for melanoma: current status and future directions.
- mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclon...
- Survival and the sentinel lymph node in melanoma.
- A phase 2 study of (99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer.
- The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).
- Molecular alternations in uveal melanoma.
- Melanoma brain metastases: is it time to reassess the bias?
- Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an I...
- Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.
- Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients.
- Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial.
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- Top Doctors:LA Area
- Fellow (FACS)
Education
-
University of Pennsylvania Health System -
Weill Cornell Medical College of Cornell University
Drug Facts
| NPI NUMBER | 1659428969 | |
| NPPES Provider LastName | FARIES | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 065103220 | |
| NPPES Provider State | CT | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 20.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659428969 |
| Last Name Of The Provider | FARIES |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
Dr. Gregory M. Senofsky, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Camelia A. Lawrence, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cary Hsu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nova M. Foster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashmi Bawa, MD |
|
|
Matthew J. Thompson, PA-C
This Doctor is OpenDoctor Recommended.
|